Skip to content

Can a series of DNA vaccine shots halt type-1 diabetes progression?

A new kind of so-called 'reverse' vaccine built to dial down the autoimmune reaction that causes type-1 diabetes is showing promise, a study of 80 patients given once-weekly injections of the vaccine for 12 weeks reveals.

Results of an early-stage clinical trial of the vaccine, just reported in Science Translational Medicine, suggest that the vaccine may be able to slow or, at best, halt the destruction of the insulin-secreting pancreatic beta cells that are targeted by an errant immune system.

When I interviewed Stanford neuroimmunologist Larry Steinman, MD, for our news release on the trial, he told me:

We’re very excited by these results, which suggest that the immunologist’s dream of shutting down just a single subset of dysfunctional immune cells without wrecking the whole immune system may be attainable... This vaccine is a new concept. It’s shutting off a specific immune response, rather than turning on specific immune responses as conventional vaccines for, say, influenza or polio aim to do.

Although there's still a very, very long way to go before this novel therapy sees widespread use, it's already exceptional in several ways.

When we hear the word "vaccine," we ordinarily think of a shot people get to fire up their immune systems so that infectious organisms will be thwarted in their never-ending efforts to invade us all. Many of us also know a vaccine is typically composed of proteins - or bits of them, or groups of them - purified or derived from the particular pathogen that vaccine targets. These proteinaceous particles serve as "mug shots" that, presented properly to the immune system's patrolling bloodhound cells, puts them in a snarling mood and greatly amps up both the speed and the volume of the immune response.

But the new vaccine a) is given after, not before, a person  gets sick; b) targets not an invading pathogen but a disorder of internal origin; c) is intended to diminish, not enhance, the immune response; and d) is made not of proteins or components or combinations of them, but of DNA containing the gene that codes for a protein (in this case, a protein called proinsulin, which is the precursor to insulin).

That's a lot of exceptions. Here's just one more: Steinman is a world authority on multiple sclerosis, but his name isn't usually associated with type 1 diabetes. Nor are those of rheumatologists P.J. Utz, MD, and Bill Robinson, MD. However, all three physicians are laser-focused on autoimmune disorders, for which type 1 diabetes - almost certainly caused by an inappropriate aggressive immune response aimed at the only cells in the body that make insulin - is a poster child.

Previously: Black hat in Alzeimer's, white hat in multiple sclerosis?, Stanford neuroimmunologist discusses recent advancements in MS research and New thinking about osteoarthritis, older people's nemesis
Photo by planetc1

Popular posts

Biomedical research
COVID-19 can infect the inner ear

Researchers say anyone with new on-set hearing loss, tinnitus or vertigo, with exposure to COVID-19, should be tested and monitored.